Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib in Asian Metastatic TNBC with HRD Signature
NCT05288127Phase 2Unknown
- Sponsor
- Universiti Malaya
- Start
- Mar 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib in triple-negative breast cancer (TNBC), sponsored by Universiti Malaya. Status: unknown.
02
Drugs
talazoparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05288127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05288127.